Ablynx Nets Another $33.5 million . The companies have the option to renew their alliance by two. 5 years. The Merck Serono financing is intended to guarantee that the companies can generate at least six study programs with proof-of-principle in another animal model. According to the successful achievement of in vivo proof-of-theory, Merck Serono said it’ll commit to taking at least four of the applications forwards with Ablynx through co-discovery and co-development plans. The study group will concentrate on discovery and development of Nanobodies spanning all Merck Serono’s primary R&D areas, including oncology, immuno-oncology, immunology, and neurology. ‘The brand new alliance is an early-stage discovery initiative, that allows the companies to rapidly explore the potential of novel targets across a range of therapeutic areas also to determine which applications should be prioritized for later-stage development,’ Edwin Moses, Ph.D., Ablynx’s chairman and CEO, said in a declaration.ACMG unveils new online educational portal focusing on genetics and genomic medicine The American University of Medical Genetics and Genomics has unveiled its brand-new ACMG Genetics Academy for Genetic and Genomic Education at an online educational portal where health care professionals interested in genetics and genomics in clinical and laboratory practice may enroll in programs and create their own private learning management center. From the fundamentals of genetics and genomics to the very best practices of clinical care, the ACMG Genetics Academy will offer you healthcare professionals and researchers access to a variety of dynamic educational forms in one user friendly site: self-paced interactive learning, webcasts, live streaming classes, online archived programs and more.